Handelsbanken Fonder AB Has $2.58 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Handelsbanken Fonder AB increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 16.2% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 31,500 shares of the company’s stock after purchasing an additional 4,400 shares during the period. Handelsbanken Fonder AB’s holdings in Vaxcyte were worth $2,579,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Vaxcyte by 68.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company’s stock worth $2,453,000 after purchasing an additional 8,685 shares during the last quarter. Natixis Advisors LLC raised its holdings in Vaxcyte by 61.1% in the 3rd quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after acquiring an additional 8,606 shares in the last quarter. Diversified Trust Co acquired a new position in Vaxcyte in the 4th quarter valued at approximately $1,433,000. Lisanti Capital Growth LLC raised its holdings in Vaxcyte by 68.1% in the 3rd quarter. Lisanti Capital Growth LLC now owns 32,515 shares of the company’s stock valued at $3,715,000 after acquiring an additional 13,175 shares in the last quarter. Finally, Curi RMB Capital LLC acquired a new position in Vaxcyte in the 3rd quarter valued at approximately $903,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of Vaxcyte in a report on Tuesday, February 11th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $127.71.

Insider Activity

In other news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00. Following the sale, the chief executive officer now directly owns 450,301 shares in the company, valued at approximately $41,630,327.45. This represents a 3.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Mikhail Eydelman sold 5,000 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $91.49, for a total value of $457,450.00. Following the sale, the senior vice president now owns 28,697 shares in the company, valued at approximately $2,625,488.53. This trade represents a 14.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 76,616 shares of company stock worth $6,766,481. Company insiders own 3.10% of the company’s stock.

Vaxcyte Trading Up 2.4 %

PCVX stock opened at $81.68 on Tuesday. Vaxcyte, Inc. has a 1-year low of $58.10 and a 1-year high of $121.06. The firm has a market cap of $10.18 billion, a P/E ratio of -17.76 and a beta of 0.98. The business’s 50 day moving average is $85.46 and its 200-day moving average is $94.99.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.